Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?» Read More
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
Fears of tepid global world took center stage this week once again, sending equity benchmarks across the board in the red this week.
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.
Sept 4- Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.. The FDA, which has granted the drug "breakthrough therapy" status for LAL deficiency in infants, was expected to make its decision by Sept. 8.
NEW YORK, Sept 1- Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving...
NEW YORK, Sept 1- Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for two drugs acquired through the deal, both enzyme-replacement therapies for ultra-rare, life threatening diseases. The treatments are awaiting U.S. approval decisions after receiving...
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
TIAA-CREF portfolio manager Saira Malik sees opportunity with a likely market correction before a Fed rate hike. Here are her picks.
A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
The next takeout target in biotech? Here are three eligible candidates
May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...
Evercore ISI’s Mark Schoenebaum couldn't believe the Alexion and Synageva deal.
*Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...
Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Wednesday: WD-40, Brocade, Zumiez, GM & more.
Some of Friday's midday movers:
Some of Monday's midday movers: